These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 19549706)

  • 61. Treatment patterns and clinical outcomes in patients with renal cell carcinoma in the UK: insights from the RECCORD registry.
    Wagstaff J; Jones R; Hawkins R; Porfiri E; Pickering L; Bahl A; Brown J; Buchan S
    Ann Oncol; 2016 Jan; 27(1):159-65. PubMed ID: 26489444
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Sunitinib in advanced metastatic non-clear cell renal cell carcinoma: a single institution retrospective study.
    Paglino C; Imarisio I; Ganini C; Morbini P; Vercelli A; Bregant C; Porta C
    Future Oncol; 2012 Dec; 8(12):1605-12. PubMed ID: 23231522
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: A real-world cost-effectiveness analysis of sequential first- and second-line treatments.
    De Groot S; Blommestein HM; Redekop WK; Sleijfer S; Kiemeney LALM; Oosterwijk E; Uyl-de Groot CA
    PLoS One; 2017; 12(5):e0177364. PubMed ID: 28531203
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Outcome of Patients With Metastatic Chromophobe Renal Cell Carcinoma Treated With Sunitinib.
    Keizman D; Sarid D; Lee JL; Sella A; Gottfried M; Hammers H; Eisenberger MA; Carducci MA; Sinibaldi V; Neiman V; Rosenbaum E; Peer A; Neumann A; Mermershtain W; Rouvinov K; Berger R; Yildiz I
    Oncologist; 2016 Oct; 21(10):1212-1217. PubMed ID: 27382030
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.
    Fernández-Pello S; Hofmann F; Tahbaz R; Marconi L; Lam TB; Albiges L; Bensalah K; Canfield SE; Dabestani S; Giles RH; Hora M; Kuczyk MA; Merseburger AS; Powles T; Staehler M; Volpe A; Ljungberg B; Bex A
    Eur Urol; 2017 Mar; 71(3):426-436. PubMed ID: 27939075
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The use of sunitinib in renal cell carcinoma: where are we now?
    Czarnecka AM; Szczylik C; Rini B
    Expert Rev Anticancer Ther; 2014 Sep; 14(9):983-99. PubMed ID: 25066545
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Sunitinib for the management of advanced renal cell carcinoma.
    Escudier B
    Expert Rev Anticancer Ther; 2010 Mar; 10(3):305-17. PubMed ID: 20214511
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis.
    Josephs D; Hutson TE; Cowey CL; Pickering LM; Larkin JM; Gore ME; Van Hemelrijck M; McDermott DF; Powles T; Chowdhury P; Karapetis C; Harper PG; Choueiri TK; Chowdhury S
    BJU Int; 2011 Oct; 108(8):1279-83. PubMed ID: 21244613
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial.
    Négrier S; Gravis G; Pérol D; Chevreau C; Delva R; Bay JO; Blanc E; Ferlay C; Geoffrois L; Rolland F; Legouffe E; Sevin E; Laguerre B; Escudier B
    Lancet Oncol; 2011 Jul; 12(7):673-80. PubMed ID: 21664867
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Sunitinib in metastatic renal cell carcinoma: Experience from single center study, efficacy and safety.
    Patel KB; Panchal HP; Karanwal AB; Parekh BB; Shah S; Prasad S
    Indian J Cancer; 2016; 53(1):118-22. PubMed ID: 27146758
    [TBL] [Abstract][Full Text] [Related]  

  • 71. First-Line Treatments for Poor-Prognosis Metastatic Renal Cell Carcinoma: Experts' Prescribing Practices and Systematic Literature Review.
    Le Saux O; Freyer G; Négrier S
    Clin Drug Investig; 2016 May; 36(5):389-99. PubMed ID: 26945986
    [TBL] [Abstract][Full Text] [Related]  

  • 72. SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer.
    Eichelberg C; Vervenne WL; De Santis M; Fischer von Weikersthal L; Goebell PJ; Lerchenmüller C; Zimmermann U; Bos MM; Freier W; Schirrmacher-Memmel S; Staehler M; Pahernik S; Los M; Schenck M; Flörcken A; van Arkel C; Hauswald K; Indorf M; Gottstein D; Michel MS
    Eur Urol; 2015 Nov; 68(5):837-47. PubMed ID: 25952317
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A Prospective Multicenter Trial of the Efficacy and Tolerability of Neoadjuvant Sunitinib for Inoperable Metastatic Renal Cell Carcinoma.
    Kim SH; Seo SI; Lee HM; Choi HY; Jeon SH; Lee HL; Kwon TG; Kim YJ; Kim WJ; Chung J
    J Korean Med Sci; 2016 Dec; 31(12):1983-1988. PubMed ID: 27822939
    [TBL] [Abstract][Full Text] [Related]  

  • 74. CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma.
    Diekstra MH; Swen JJ; Boven E; Castellano D; Gelderblom H; Mathijssen RH; Rodríguez-Antona C; García-Donas J; Rini BI; Guchelaar HJ
    Eur Urol; 2015 Oct; 68(4):621-9. PubMed ID: 25930089
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial.
    Vinik A; Bottomley A; Korytowsky B; Bang YJ; Raoul JL; Valle JW; Metrakos P; Hörsch D; Mundayat R; Reisman A; Wang Z; Chao RC; Raymond E
    Target Oncol; 2016 Dec; 11(6):815-824. PubMed ID: 27924459
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Efficacy of sunitinib in patients with metastatic or unresectable renal cell carcinoma and renal insufficiency.
    Poprach A; Bortlicek Z; Melichar B; Lakomy R; Svoboda M; Kiss I; Zemanova M; Fiala O; Kubackova K; Coufal O; Pavlik T; Dusek L; Vyzula R; Buchler T
    Eur J Cancer; 2015 Mar; 51(4):507-513. PubMed ID: 25577735
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Health-related quality of life in Japanese patients with metastatic renal cell carcinoma treated with sunitinib.
    Miyake H; Harada K; Kusuda Y; Fujisawa M
    Int J Clin Oncol; 2013 Apr; 18(2):220-5. PubMed ID: 22198800
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma.
    Bedke J; Rini BI; Plimack ER; Stus V; Gafanov R; Waddell T; Nosov D; Pouliot F; Soulières D; Melichar B; Vynnychenko I; Azevedo SJ; Borchiellini D; McDermott RS; Tamada S; Nguyen AM; Wan S; Perini RF; Rhoda Molife L; Atkins MB; Powles T
    Eur Urol; 2022 Oct; 82(4):427-439. PubMed ID: 35843776
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Flashback Foreword: Pazopanib in Renal Cell Carcinoma and Overall Survival With Sunitinib Versus Interferon-α in Metastatic Renal Cell Carcinoma.
    Carducci MA
    J Clin Oncol; 2023 Apr; 41(11):1955-1956. PubMed ID: 37018918
    [No Abstract]   [Full Text] [Related]  

  • 80. Quality of life in patients with advanced renal cell carcinoma treated with temsirolimus or interferon-alpha.
    Yang S; de Souza P; Alemao E; Purvis J
    Br J Cancer; 2010 May; 102(10):1456-60. PubMed ID: 20461090
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.